2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2114 Nanopore long read sequencing with adaptive sampling for comprehensive, amplification-free genetic profiling of chronic lymphocytic leukemia in a single assay

Cornelis A.M. van Bergen, PhD, Edwin Quinten, BS2, Ela Wierciak, BSc3, Sultan Tleulov, BSc4, Ruben AL De Groen, PhD, MSc5, Hailiang Mei, PhD6, Szymon M Kielbasa, PhD7, Susan Kloet, PhD8, Hendrik Veelken, MD PhD9
1 Leiden University Medical Center, Leiden, Netherlands
2 Leiden University Medical Center, Leiden, Netherlands
3 AGH University of Krakow, Krakow, Poland
4 Leiden University Medical Center, Leiden, Netherlands
5 Leiden University Medical Center, Leiden, Netherlands
6 Leiden University Medical Center, Leiden, Netherlands
7 Leiden University Medical Center, Leiden, Netherlands
8 Leiden University Medical Center, Leiden, Netherlands
9 Leiden University Medical Center, Leiden, Netherlands

Full diagnostic characterization of chronic lymphocytic leukemia (CLL) requires (1) sequencing of the heavy and light chains of the expressed clonotypic B-cell receptor (BCR), (2) sequencing of recurrently mutated genes, and (3) detection of recurrent copy number variations (CNV) and (4) of complex karyotypes. Furthermore, the incidence of CLL is governed by germline risk alleles. Capturing these features currently requires diverse genetic and molecular assays that frequently involve DNA amplification with the potential for sequence errors. Oxford Nanopore Technology (ONT) feeds long single DNA strands through a membrane-embedded nanopore and calls the 4 conventional ACGT bases plus methylcytosine by distinct changes in ion current across the membrane. Adaptive sampling can be applied to terminate sequencing of any DNA fragment early whose sequence does not correspond to a pre-defined region of interest. Here, we explore ONT long-read sequencing with adaptive sampling as an amplification-free platform to capture all essential genetic information on individual CLL patients.

CD5+ cells were enriched from 16 CLL samples with immunomagnetic beads. Genomic DNA from enriched CLL cells, blood cells of 5 healthy siblings and a CLL patient in remission was isolated (Monarch kit), barcoded, and combined in 4 pools of 5-6 samples. Pooled DNA was sequenced on a ONT PromethION 24 device with adaptive sampling applied to 179 genomic regions with a combined length of 47.1 Mb to achieve sufficient depth in 89 CLL risk loci, 64 HLA loci and recurrently mutated CLL genes, 32 regions within recurrent CLL CNV, and complete immunoglobulin gene loci. Raw FASTQ were mapped alternatively to the hg38 and T2T reference genomes. Typical yields were 108 reads per sample with read lengths of 10-40 kb in adaptively sampled regions and <600 bp genome-wide outside of adaptive sampling. Effective adaptive sampling was indicated by a median read depth of 22 reads (range: 18 - 32) per CLL risk locus. Somatic single nucleotide variants (SNV) were called in BAM files as the intersection of Clair3 and DeepVariant output. Calculation of individual polygenic risk scores (Kleinstern, Leukemia 2022) yielded an average of 8.41 (±0.68) for CLL patients and 8.05 (±0.67) for their siblings.

For detection of pathogenic mutations in CLL genes, called SNV and small indels were filtered for single nucleotide polymorphisms and subsequently by variant effect prediction for “deleterious” SIFT scores (<0.05) and “damaging” Polyphen scores (>0.85). 22 SNV predicted to be pathogenic were identified in 16 CLL genes of 12 CLL samples (including two TP53 mutations), as well as 5 indels in 4 genes of 5 CLL samples.

In adaptively sampled regions, ONT detected all 14 recurrent CNV reported by routine FISH diagnostics performed in 8 CLL samples. In addition, CNV were detected in low-coverage regions by normalizing average read count of 10kb-bins and searching for CNV in >100 consecutive bins (1 Mb). With the hg38 reference, this approach yielded 24 non-recurrent CNV (8 on chromosome 1; 4 on chr. 10) in 9 CLL samples (56%) and correctly identified all 4 CLL with a complex karyotype as detected by metaphase cytogenetics. The T2T reference yielded distinct false-positive CNV gains.

To identify the clonotypic BCR, a reference library was built with all IGV and IGJ reference sequences from IMGT, with IGJ sequences extended by their 3’ adjacent intronic 250 bp. ONT FASTQ reads were mapped to this reference library by minimap2. Candidate reads spanning a V(D)J recombination event were defined by the presence of at least one IGV gene and at least one IGJ gene from the same immunoglobulin locus on the same read. These reads were analyzed by IMGT/V-QUEST for productive VDJ or VJ sequences, respectively. Productive BCR sequences matched V(D)J cDNA sequences obtained by bulk ARTISAN or single-cell 10X template-switching RT-PCR as standard.

Long-read ONT sequencing appears to be a promising platform for amplification-free, comprehensive genetic testing in CLL in a single assay. Input of approximately 5 million malignant cells provides sufficient depth to call CLL risk alleles, somatic mutations, structural variants including complex karyotypes, as well as BCR mutational status, IGV usage, the IGLV3-21R110 variant, and CLL BCR stereotypes in a reliable, convenient, and cost-efficient manner. Future prospects include assignment to prognostically important methylation types (Oakes, Nat.Gen. 2016).

Hendrik Veelken, MD PhD: No relevant conflicts of interest to declare.